

ANETA PHARMACEUTICALS PRIVATE LIMITED

CIN: U24230GJ2022PTC131644

Reg. Off: 808, SHILP ZAVERI, SHYAMAL CROSS ROAD SATELITE, Ahmedabad,
AHMEDABAD, Gujarat, India, 380015

Email: acc.anetapharma@gmail.com

NOTICE OF ANNUAL GENERAL MEETING

To
The members of the company
M/s. Aneta Pharmaceuticals Private Limited

The Notice with respect to 2nd Annual General Meeting of the Company to be convened as follows;

Annual General Meeting No : 2nd Annual General Meeting
Date of Notice : 23rd September, 2024
Date of AGM : 30th September, 2024
Day of AGM : Monday
Time of AGM : 4.00 p.m.
**Place of AGM :808, SHILP ZAVERI, SHYAMAL CROSS ROAD SATELITE,
AHMEDABAD, Gujarat, India, 380015**

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Profit and Loss Statement for the financial year ended March 31, 2024 and the Balance Sheet as on March 31, 2024 together with the Reports of the Directors and the Statutory Auditors' thereon.

NOTES:

1. A member of the Company entitled to attend and vote at the said meeting is entitled to appoint a proxy to attend and vote instead of himself and a proxy need not be a member of the company. A person can act as a proxy on behalf of members not exceeding fifty and holding in the aggregate not more than ten percent of the total share capital of the Company carrying voting rights. A member holding more than ten percent of the total share capital of the Company carrying voting rights may appoint a single person as proxy and such person shall not act as a proxy for any other person or shareholder.
2. Corporate Members intending to send their authorized representatives to attend the Meeting are requested to send to the Company, a certified copy of the Board Resolution authorizing the representative to attend and vote on their behalf at the Meeting.
3. Members are requested to notify immediately any change in their address if any, to the Company.

**For and on behalf of Board of Directors,
M/s. Aneta Pharmaceuticals Private Limited**

Date: 23rd September, 2024

ANETA PHARMACEUTICALS PRIVATE LIMITED

CIN: U24230GJ2022PTC131644

Reg. Off: 808, SHILP ZAVERI, SHYAMAL CROSS ROAD SATELITE, Ahmedabad,
AHMEDABAD, Gujarat, India, 380015

Email: acc.anetapharma@gmail.com

Place: Ahmedabad

Sd/-

Mr. Nitin Patel

Director/ Chairman

DIN: 05225550

Reg. Off: 808, SHILP ZAVERI, SHYAMAL CROSS ROAD SATELITE, Ahmedabad, AHMEDABAD, Gujarat, India, 380015
Email: acc.anetapharma@gmail.com

DIRECTORS' REPORT

To,
The Shareholders
M/s. ANETA PHARMACEUTICALS PRIVATE LIMITED

Your Directors have a pleasure in presenting their 2nd Annual Report together with Audited Balance Sheet as on 31st March, 2024 and Profit & Loss Statement for the year ended on 31st March, 2024.

1. FINANCIAL PERFORMANCE: (Amount in Hundred.)

Particulars	2023-24	2022-23
Sales & Other Income	9,09,447	3,31,581
Less: Expenses	13,46,768	(3,36,646)
Profit / (Loss) Before Depreciation & Finance Cost	(4,37,321)	(5,065)
Less: Finance Cost	(80,331)	0
Less: Depreciation	(74,162)	688
Profit / (Loss) Before Depreciation & Tax	(5,91,814)	(5,753)
Profit / (Loss) before Tax	(5,91,814)	(5,753)
Less: Income Tax	-	0
Deferred Tax	(39,221)	(326)
Short Provision of IT of Earlier Year	-	0
Profit / (Loss) after Tax	(6,31,035)	(5,427)

2. PERFORMANCE OVERVIEW:

During the year under review, your Company has continued to carry on the business activities of manufacturing of medicines, allopathic, ayurvedic, homeopathic, unani, patent medicines, lotions, cosmetics, formulations, pills, injection, tablets, capsules, ointments, herbs, cosmetics, toiletries etc. Total revenue from operation stood at **Rs. 8,96,18,700 (Eight Crore Ninety Six Lacs Eighteen Thousand Seven Hundred Only)** as against **Rs. 3,31,58,100(Three Crore Thirty One Lacs Fifty Eight Thousand Hundred Only)** for the previous financial year. Company Making Loss Continuously due to higher employee cost, depreciation and finance cost. The Management of the Company is thriving hard to achieve higher operating leverage and better margin.

3. DETAILS REGARDING SUBSIDIARY COMPANIES, ASSOCIATE COMPANIES

ANETA PHARMACEUTICALS PRIVATE LIMITED
CIN: U24230GJ2022PTC131644

Reg. Off: 808, SHILP ZAVERI, SHYAMAL CROSS ROAD SATELITE, Ahmedabad, AHMEDABAD, Gujarat, India, 380015
Email: acc.anetapharma@gmail.com

AND JOINT VENTURE COMPANIES:

No Company during the year has become or ceased to be Company's Subsidiary, Joint Ventures or Associate Companies. Apart from that the company does not have any subsidiary, JV or associate company during the year under review. Hence disclosures in Form AOC-1 are not applicable for the year under review.

4. PERFORMANCE AND FINANCIAL POSITION OF ASSOCIATE, JOINT VENTURE OR SUBSIDIARY COMPANIES:

The Company does not have any Associate or Joint Venture or Subsidiary Company; hence disclosure requirement with respect to performance and financial position of such Associate or Joint Venture or Subsidiary Company is not applicable during the year under review.

5. MATERIAL CHANGES AND COMMITMENTS:

During the year there were no material changes and commitments affecting the financial position of the Company which have occurred between the end of financial year of the Company to which the financial statements relate and the date of the Board of Director's report.

6. REASONS FOR REVISION OF FINANCIAL STATEMENT OR REPORT:

During the year, the financial statements or report was not revised. Hence disclosures requirement is not applicable.

7. DIVIDEND:

During the year, the management has decided not to declare dividend with a view to conserve the resources and to maintain the liquidity so as to explore new business opportunities as and when comes.

8. RESERVES:

In view of losses, the Company has not proposed to carry or transfer any amount to any reserves during the financial year under review.

9. DIRECTORS & KEY MANAGERIAL PERSONNEL:

During the year, the requirement to appoint Key Managerial Personnel was not applicable to the Company. No Director has been appointed or resigned from the company during the year under review.

As per the Articles of Association of the company or as per the provisions of the

ANETA PHARMACEUTICALS PRIVATE LIMITED
CIN: U24230GJ2022PTC131644

Reg. Off: 808, SHILP ZAVERI, SHYAMAL CROSS ROAD SATELITE, Ahmedabad, AHMEDABAD, Gujarat, India, 380015

Email: acc.anetapharma@gmail.com

Companies Act, 2013, none of the Directors of your Company are liable to retire by rotation during the financial year under review.

10. INDEPENDENT DIRECTOR:

Your Company is not covered under class of Company as prescribed under Section 149(3) of the Companies Act, 2013 read with Rule 4 of Companies (Appointment and Qualification of Directors) Rules, 2014, hence, no disclosures required under sections 134(3)(d), Section 149(6) and 149(10) of the Companies Act, 2013.

11. DIRECTORS' RESPONSIBILITY STATEMENT:

Pursuant to the requirement of section 134(5) of the Companies Act, 2013, with respect to Directors' Responsibility Statement, it is hereby confirmed:

- a. that in the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- b. that the Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the Profit and loss of the company for that Period;
- c. that the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- d. that the Directors had prepared the annual accounts on a going concern basis; and
- e. that the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

12. DETAILS OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS:

The Company is well equipped with adequate internal financial controls. The Company has a continuous monitoring mechanism which enables the organisation to maintain with the same standard of the control systems and helps them in managing any default on timely basis because of strong reporting mechanisms followed by the Company.

Reg. Off: 808, SHILP ZAVERI, SHYAMAL CROSS ROAD SATELITE, Ahmedabad, AHMEDABAD, Gujarat, India, 380015
Email: acc.anetapharma@gmail.com

13. FORMAL EVALUATION BY BOARD OF ITS OWN PERFORMANCE:

Being an unlisted Company or having paid up capital of less than Rs. 25 Crores, the Statement in respect of Formal Evaluation by the Board of its own performance and that of its committees and individual directors are not applicable to the Company.

14. NUMBER OF MEETINGS OF BOARD:

The Board of Directors duly met 6 (Six) times during the financial year under review on 21st May, 2023, 13th September, 2023, 30th September, 2023, 15th December, 2023, 19th February, 2024, 05th March, 2024.

Further, the Board of Directors of the Company confirms the compliance with the requirement of the Secretarial Standards as issued by the Institute of the Company Secretaries of India and notified by the Ministry of Corporate Affairs. The Prescribed quorum was present for all the Meetings.

15. ISSUE OF EQUITY SHARES WITH DIFFERENTIAL VOTING RIGHTS / SWEAT EQUITY SHARES / EMPLOYEE STOCK OPTION SCHEME:

During the year under review, the Company has not issued any equity shares with differential voting rights or sweat equity shares or employee stock option scheme. Hence disclosure regarding the same is not required to be given.

16. AUDITORS & AUDITORS' REPORT:

M/s. Nivedita & Company, Chartered Accountants, Ahmedabad (Firm Registration No. 152122W), have been appointed as Statutory Auditors of the Company for a term of Five years in the 1st Annual General Meeting till the conclusion of 6th Annual General Meeting to be held in the Year 2029. Further, as per recent amendment no ratification of such appointment is required in every subsequent Annual General Meeting.

The Board has duly reviewed the Statutory Auditor's Report on the Accounts. The observations comments and notes of Auditor are self explanatory and do not call for any further explanation/clarification.

17. COST AUDITOR

Your company is not required to appoint cost auditors pursuant to Section 148 and all other applicable provisions, if any, of the Companies Act 2013 and the Rules made there under, for the financial period under review.

18. VIGIL MECHANISM:

ANETA PHARMACEUTICALS PRIVATE LIMITED
CIN: U24230GJ2022PTC131644

Reg. Off: 808, SHILP ZAVERI, SHYAMAL CROSS ROAD SATELITE, Ahmedabad, AHMEDABAD, Gujarat, India, 380015
Email: acc.anetapharma@gmail.com

As the Company is neither listed Company nor falling under criteria laid down under rule 7 of Companies (Meetings of Board and its Powers) Rules, 2014, hence the vigil mechanism is not applicable to the Company during the financial year under review.

19. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORK PLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:

As the Company is not having ten or more women employees as provided under the Sexual Harassment of Women at work Place (Prevention, Prohibition and Redressal) Act, 2013, hence the Company is not required to make any policy with respect to the same. However, the Company ensures security of woman at workplace.

There was no case reported under the Act during the period reviewed under year.

20. CORPORATE SOCIAL RESPONSIBILITY (CSR):

The Company is not covered under class of Companies as specified under Section 135 of the Companies Act, 2013, hence, reporting requirement pertaining to CSR Committee and CSR is not applicable to our Company during the year under review under section Sec 134(3)(o) read with Rule 9 of Companies (Accounts) Rules, 2014 and Section 135 of the Companies Act, 2013.

21. ANALYSIS OF REMUNERATION:

The Company is not listed on any recognized stock exchange; hence disclosure regarding the ratio of the remuneration of each Director to the median employee's remuneration and other details are not applicable to the Company.

22. POLICY ON DIRECTOR'S APPOINTMENT & REMUNERATION:

Requirement of Nomination and Remuneration Committee is not applicable to the Company; however, the Company's remuneration policy is directed towards rewarding performance based on review of achievements periodically.

23. RISK MANAGEMENT POLICY:

The Company is not required to formulate Risk Management Policy.

24. PARTICULARS OF EMPLOYEES:

No employee of the Company drawing remuneration in excess of the limits specified under Section 134 of the Companies Act, 2013 read with Rule 5(2) of the Companies (Appointment & Remuneration of Managerial Personnel) Rules, 2014, and hence disclosure requirement for the same is not applicable to the Company for the financial year under review.

Reg. Off: 808, SHILP ZAVERI, SHYAMAL CROSS ROAD SATELITE, Ahmedabad, AHMEDABAD, Gujarat, India, 380015
Email: acc.anetapharma@gmail.com

25. DETAILS ON CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS & OUTGO:

(A) Conservation of energy	
(i) the steps taken or impact on conservation of energy	The activities carried out by the Company are power intensive and the cost of the energy is Rs 57,58,300.
(ii) the steps taken by the company for utilizing alternate sources of energy	
(iii) the capital investment on energy conservation equipments	
(B) Technology absorption	
(i) the efforts made towards technology absorption	The Company has not imported any technology during the year.
(ii) the benefits derived like product improvement, cost reduction, product development or import substitution	
(iii) in case of imported technology (imported during the last three years reckoned from the beginning of the financial year) (a) the details of technology imported; (b) the year of import; (c) whether the technology been fully absorbed; (d) if not fully absorbed, areas where absorption has not taken place, and the reasons thereof; and	
(iv) the expenditure incurred on Research and Development	
(C) Foreign exchange earnings and Outgo	
The Foreign Exchange earned in terms of actual inflows during the year and The Foreign Exchange outgo during the year in terms of actual outflows	During the year Earnings in Foreign Exchange Was Rs. NIL and Value of Imports of Material and Services was Rs. 19,99,800 and capital goods was Rs. NIL.

26. FIXED DEPOSITS:

During the year under report, your Company has accepted exempted fixed deposits from their Member's and Director. Hence, disclosures as required pursuant to Rule 8(5)(v) of Companies (Accounts) Rules, 2014 are not applicable for the financial year under review.

Further Company has accepted exempted deposit from directors of the company and the return of same has been filed with ROC vide form DPT-3, pursuant to rule 16 of Companies (Acceptance of Deposits) Rules, 2014.

ANETA PHARMACEUTICALS PRIVATE LIMITED
CIN: U24230GJ2022PTC131644

Reg. Off: 808, SHILP ZAVERI, SHYAMAL CROSS ROAD SATELITE, Ahmedabad, AHMEDABAD, Gujarat, India, 380015
Email: acc.anetapharma@gmail.com

27. CORPORATE GOVERNANCE:

Our Company is an unlisted entity; hence the requirement of Corporate Governance is not applicable to our Company during the financial year under review.

28. EXTRACT OF ANNUAL RETURN:

Pursuant to Companies (Amendment) Act, 2017 the Companies are not required to attach Extract of Annual Return in Form MGT-9, however, if the Company is maintaining any website then in such case the Company is required to place copy of Annual Return on the website of the Company and web link of the same shall required to be given in Director's Report pursuant to provisions of Section 92(3) of the Companies Act, 2013 read with the Companies (Management and Administration) Rules, 2014. In our case the Company is not having any official web site and hence requirement of placing Annual Return on the web site of the Company is not applicable.

29. PARTICULARS OF LOANS, INVESTMENTS OR GUARANTEES UNDER SECTION 186 OF THE COMPANIES ACT, 2013:

The Company hasn't given any loan to a person or a body corporate, neither has it provided any guarantee or security in connection with a loan to any other body corporate or a person as per section 186 of The Companies Act, 2013 for the financial year under review.

30. RELATED PARTY TRANSACTION:

The Company has neither entered in to related party transaction which is not at arm's length base nor does have any material related party transaction for the financial year under review. Thus, details with respect to Related Party Transaction in prescribed Form AOC-2, is not applicable to the Company.

31. MATERIAL ORDERS PASSED BY THE REGULATOR/COURT:

During the year under review there is no significant and material order passed by the regulators or courts or tribunals impacting the going concern status and Company's operations in future.

32. ACKNOWLEDGEMENT:

Your Directors wish to place on record their sincere appreciation to the Customers, Employees, Professionals, and Bankers to the Company for their Cooperation and contribution in the affairs of the Company.

ANETA PHARMACEUTICALS PRIVATE LIMITED
CIN: U24230GJ2022PTC131644

Reg. Off: 808, SHILP ZAVERI, SHYAMAL CROSS ROAD SATELITE, Ahmedabad, AHMEDABAD,
Gujarat, India, 380015
Email: acc.anetapharma@gmail.com

**For and on behalf of Board of Directors,
M/s. Aneta Pharmaceuticals Private Limited**

Date: 23rd September, 2024
Place: Ahmedabad

ANETA PHARMACEUTICALS PVT. LTD.



Mr. Nitin Patel
Director/ Chairman
DIN: 05225550

DIRECTOR



NIVEDITA & COMPANY

Chartered Accountants

100, Sakar County, Near Shanti Asiatic School, Shela Road, Ahmedabad -380058

Independent Auditor's Report

To the Members of Aneta Pharmaceuticals Private Limited

Report on the Audit of the financial Statements

Opinion

We have audited the accompanying financial statements of Aneta Pharmaceuticals Private Limited ("the Company"), which comprise the Balance Sheet as at March 31, 2024, and the Statement of Profit and Loss and the Cash Flow Statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Accounting Standards specified under section 133 of the Act read with the Companies (Accounting Standards) Rules, 2021 ("AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2024, and its profit/loss and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing (SAs), as specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Financial Statements' section of our report. We are independent of the Company in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Other Information

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Annual report but does not include the financial statements and our auditor's report thereon. **The above-referred information is expected to be made available to us after the date of this audit report.**





NIVEDITA & COMPANY

Chartered Accountants

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

When we read the information, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance and take appropriate actions necessitated by the circumstances & the applicable laws and regulations

Responsibilities of Management for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, cash flows and changes in equity of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards (AS) specified under section 133 of the Act read with the Companies (Accounting Standards) Rules. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:





NIVEDITA & COMPANY

— Chartered Accountants —

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.





NIVEDITA & COMPANY

Chartered Accountants

Report on Other Legal and Regulatory Requirements

1. The Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act and on the basis of such checks of the books and records of the Company as we considered appropriate and according to the information and explanations given to us, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - (c) The Balance Sheet, the Statement of Profit and Loss, the Cash Flow Statement and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account;
 - (d) In our opinion, the financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 Companies (Accounts) Rules, 2014.
 - (e) On the basis of the written representations received from the directors as on March 31, 2023 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2023 from being appointed as a director in terms of Section 164 (2) of the Act;
 - (f) With respect to the adequacy of the internal financial controls with reference to the financial statements and the operating effectiveness of such controls, Pursuant to Notification G.S.R. 583(E) dated June 13, 2017 issued by the Ministry Of Corporate Affairs, Section 143(3)(i) of the Act is not applicable to the Company and accordingly this report does not state whether the Company has adequate internal financial controls over financial reporting in place and the operating effectiveness of such controls.
 - (g) with respect to the other matters to be included in the Auditors' Report in accordance with the requirements of section 197(16) of the Act, the same is not applicable to the company, it being a private company.





NIVEDITA & COMPANY

— Chartered Accountants —

3. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
- (i) The Company does not have any pending litigations which would impact its financial position.
 - (ii) The Company did not have any long-term contracts including derivative contracts as at March 31,2024.
 - (iii) There were no amounts that were, required to be transferred, to the Investor Education and Protection Fund by the Company.
- 4.
- a. The Management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - b. The Management has represented, that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
 - c. Based on the audit procedures that has been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e) contain any material misstatement.
5. The Company has not declared or paid any dividend during the year






NIVEDITA & COMPANY

Chartered Accountants

- i. Based on our examination which included test checks, the Company has used accounting software for maintaining its books of account for the financial year ended March 31, 2024, which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with.

FOR, NIVEDITA & COMPANY
CHARTERED ACCOUNTANTS
FIRM REGISTRATION NO. 152122W


NIVEDITA THATOI
(PARTNER)

MEMBERSHIP NO. 194052

UDIN: 24194052BKJML04992

PLACE: AHMEDABAD

DATE: 23/09/2024





NIVEDITA & COMPANY

— Chartered Accountants —

Annexure A referred to in paragraph 1 of our report of even date under the heading "Report on Other Legal and Regulatory Requirements"

In terms of the information and explanations sought by us and given by the company and the books of account and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that:

- I (a) (A) The Company has generally maintained proper records showing full particulars, including quantitative details and situation of Property, Plant & Equipment, except in case of certain plant and machinery, where the company is in the process of updating the records for situation of these assets.
- (B) The Company has maintained proper records, where relevant, Showing full particulars of intangible assets.
- (b) The Company has a program of verification to cover all the items of Property, Plant and Equipment in a phased manner over a period of 3 years which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the program, certain Property, Plant and Equipment were physically verified by the management during the year. According to the information and explanations given to us, no material discrepancies were noticed on such verification.
- (c) With respect to immovable properties (other than properties where the Company is the lessee and the lease agreements are duly executed in favor of the Company) disclosed in the financial statements included in property, plant and equipment and according to the information and explanations given to us and based on the examination of the documents, the title deeds of such immovable properties are held in the name of the company as at the balance sheet date.
- (d) The Company has not revalued its Property, Plant and Equipment or intangible assets during the year.
- (e) Based on the information and explanations furnished to us, no proceedings have been initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder. Accordingly, the requirement to report on clause 3(i)(e) of the Order is not applicable to the Company and hence not reported upon.





NIVEDITA & COMPANY

Chartered Accountants

- ii (a) The inventories, were physically verified during the year by the management at reasonable intervals. In our opinion and according to the information and explanations given to us, the coverage and procedure of such verification is appropriate. No discrepancies of 10% or more in aggregate for each class of inventory were noticed.
- (b) The Company has not been sanctioned working capital limits in excess of ₹ five crores in aggregate from banks or financial institutions during the year on the basis of security of current assets. Accordingly, the requirement to report on clause 3(ii)(b) of the Order is not applicable to the Company and hence not reported upon.
- iii (a) The Company has not granted any loan or provide any guarantee or security or granted any loans or advances in the nature of loans secured or unsecured to companies, firms, Limited liability partnerships or any other parties during the year Accordingly paragraph 3(iii)(a), (c), (d), (e), (f) of the Order is not applicable to the Company.

The investments made during the year are, prima facie not prejudicial to the interest of the company.

- iv The company has complied with the provision of sec 185 and sec 186 of company act with respect to its investment made during the year.

- v According to the information and explanations given to us, the Company has accepted loan from its shareholder which falls in the nature of deposit during the year, and for the same company has carried out the compliances with Section 73 to 76 of the Act as applicable.

According to the information and explanations given to us, no order has been passed by the Company Law Board or the National Company Law Tribunal or the Reserve Bank of India or any Court or any other tribunal on the Company.

- vi Maintenance of cost records as specified by the Central Government under sub-section (1) of section 148 of the Companies Act is not applicable to company being a company incorporated during the reporting year only. Hence reporting under paragraph 3 (vi) of the Order is not applicable.



(a)

Undisputed statutory dues including goods and services tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and other statutory dues have generally been regularly deposited with the appropriate authorities,



NIVEDITA & COMPANY

Chartered Accountants

where applicable, though there has been a slight delay in a few cases. According to the information and explanations given to us and based on audit procedures performed by us, undisputed amounts payable in respect of professional tax amounting to rupees 2,06,200/- were outstanding, at the year end, for a period of more than six months from the date they became payable.

- (b) According to the information and explanations given to us, there are no amounts in respect of income tax/ custom duty / Goods and Service Tax that have not been deposited with the appropriate authorities on account of any dispute.

viii

In our opinion and according to the information and explanations given to us and on the basis of our examination of the records of the Company. We confirm that we have not come across any transactions not recorded in the books of account which have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.

ix

- (a) The Company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender.
- (b) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- (c) In our opinion, term loans availed by the Company during the year, were applied by the Company for the purposes for which the loans were obtained.
- (d) According to the information and explanations given to us and on an overall examination of the balance sheet of the company, we report that no funds raised on short-term basis have been used for long-term purposes by the company
- (e) The Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries or associates during the year and hence, reporting under clause (ix)(e) of the Order is not applicable
- (f) The Company has not raised loans during the year on the pledge of securities held in its subsidiaries or associate companies





NIVEDITA & COMPANY

Chartered Accountants

- (x) (a) The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) during the year and hence reporting under clause (x)(a) of the Order is not applicable.
- (b) The company has not made any preferential allotment or private placement of shares or convertible debentures during the year and hence reporting under this clause is not applicable to company.
- (xi) (a) To the best of our knowledge, no material fraud by the Company and no material fraud on the Company has been noticed or reported during the year.
- (b) No report under section 143(12) of the Companies Act, 2013, has been filed in form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and up to the date of this report.
- (c) As represented to us by the Management there are no whistle blower complaints received by the Company during the year.
- (xii) The Company is not a Nidhi Company and hence reporting under clause (xii) of the Order is not applicable.
- (xiii) In our opinion and according to the information and explanations given to us, the transactions with related parties are in compliance with Section 188 of the Companies Act, 2013, where applicable, and the details of the related party transactions have been disclosed in the notes to the financial statements as required by the applicable accounting standards.
- Further, the Company is not required to constitute an Audit Committee under Section 177 of the Act, and accordingly, to this extent, the provisions of this Clause are not applicable to the Company.
- (xiv) The Company has an internal audit system commensurate with the size and nature of its business. Provision of sec 138 of the companies Act, 2013 read with rule 13 of the companies (accounts) Rules, 2014 is not applicable to company. Hence reporting under this clause is not applicable to the company.
- (xv) In our opinion, during the year, the Company has not entered into any non-cash transactions with any of its directors or persons connected with such directors and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.





NIVEDITA & COMPANY

Chartered Accountants

- (xvi) (a) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Hence, reporting under clause (xvi)(a) of the Order are not applicable.
- (b) The Company has not conducted non-banking financial / housing finance activities during the year. Accordingly, the reporting under Clause 3(xvi)(b) of the Order is not applicable to the Company.
- (c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.
- (d) In our opinion, there is no core investment company within the Group (as defined in the Core Investment Companies (Reserve Bank) Directions, 2016) and accordingly reporting under Clause 3(xvi)(d) of the Order is not applicable.
- (xvii) The company has incurred cash losses in the financial year under audit, the total amount of cash losses is of Rupees 5,16,32,472 only.
- (xviii) There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.
- (xix) According to the information and explanations given to us and on the basis of the financial ratios , ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the standalone financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.



- (xx) (a) Sec 135 of the companies Act, 2013 for corporate social responsibility is not applicable to the company. Hence, reporting under clause 3(xx)(a) of the order is not applicable.



NIVEDITA & COMPANY

Chartered Accountants

(b) Sec 135 of the companies Act, 2013 for corporate social responsibility is not applicable to the company. Hence, reporting under clause 3(xx)(b) of the order is not applicable.

(xxi) The reporting under Clause 3(xxi) of the Order is not applicable in respect of audit of financial statements. Accordingly, no comment in respect of the said clause has been included in this report.

FOR, NIVEDITA & COMPANY
CHARTERED ACCOUNTANTS
FRNO. 152122W

J. Thatoi

NIVEDITA THATOI
(PARTNER)
MEMBERSHIP NO. 194052
UDIN:
PLACE: AHMEDABAD
DATE: 23/09/2024



Aneta Pharmaceuticals Private Limited
CIN: U24230GJ2022PTC131644
Balance Sheet as at 31st March, 2024

(Rupees in Hundred,
Unless otherwise Stated)

Particulars	NOTE NO.	As at 31-03-24	As at 31-03-23
EQUITY AND LIABILITIES			
Shareholders' Funds			
Share Capital	2	450,000	450,000
Reserves and Surplus	3	(636,462)	(5,427)
		(186,462)	444,573
Non Current Liabilities			
Long-term borrowings	4	4,501,785	1,577,037
Long Term Provisions	5	1,453	132
Deferred Tax Liability (Net)	6	38,895	-
Current Liabilities			
Trade Payable	7		
- Total outstanding dues of micro enterprises and small enterprises		253,749	2,230
- Total outstanding dues of creditors other than micro enterprises and small enterprises		784,874	24,488
Other Current Liabilities	8	105,470	10,565
Short Term Borrowing	9	403,385	30,255
Short Term Provisions	10	7	0
		1,547,486	67,538
TOTAL		5,903,157	2,089,281
ASSETS			
Non - Current Assets			
Property, Plant and Equipment and Intangible Assets			
Property, Plant and Equipment	11	3,311,544	2,500
Intangible Assets	12	4,233	882
Capital Work-in-progress	13	-	786,629
		3,315,777	790,012
Deferred Tax Assets (Net)	6	-	326
Long Term Loans & Advances	14	560	876,560
Other Non- Current Assets	15	129,147	100,941
Current Assets			
Trade Receivables	16	572,882	-
Cash and Bank Balances	17	76,150	159,501
Inventory of trading goods	18	966,393	-
Short Term Loans And Advances	19	421,902	100,229
Other Current Assets	20	420,347	61,712
		2,457,674	321,442
TOTAL		5,903,158	2,089,281

Significant Accounting Policies

This is the Balance sheet referred to in our report of even date.

The accompanying notes are integral part of financial statements

For Nivedita & Company

Chartered Accountants
Firm Reg No. 152122W

[Signature]

CA. Nivedita Thatoi
(Partner)

M. No: 194052

UDIN : 24194052BKJMLD4992

Place : Ahmedabad

Date : 23/09/2024



For and on behalf of the board of
directors of Aneta Pharmaceuticals
Private Limited
CIN: U24230GJ2022PTC131644

[Signature]

NITIN J PATEL SUBHASH J CHHABHAIYA
(Director) (Director)
DIN:05225550 DIN: 07090890

Place : Ahmedabad
Date : 23/09/2024



Aneta Pharmaceuticals Private Limited
CIN: U24230GJ2022PTC131644
Provisional Statement of Profit and Loss For the Period ended 31st March, 2024

(Rupees in Hundred, Unless
otherwise Stated)

Particulars	NOTE NO.	Period Ended 31-03-24	Year ended 31-03-23
INCOME			
Revenue from Operations	21	896,187	327,527
Other Income	22	13,259	4,054
TOTAL INCOME (I+II)		909,447	331,581
EXPENSES			
Cost of Material Consume	23	186,557	-
Purchase of Stock In Trade	24	1,355,257	324,885
Changes in inventories of finished goods, work-in-progress and stock-in-trade	25	(794,453)	-
Employee Benefits Costs	26	330,404	4,178
Finance Cost	27	80,331	-
Depreciation and Amortization Expenses	11-12	74,162	688
Other Expenses	28	269,004	7,583
TOTAL EXPENSES		1,501,261	337,334
Profit before tax		(591,814)	(5,753)
Tax Expenses :			
Current income tax		-	-
Deferred Tax (Credit)		39,221	(326)
Short / (excess) provision for tax of earlier years			
Total tax expenses			
Profit for the year		(631,035)	(5,427)
Earnings per equity share :			
Basic and Diluted		(140)	(1.21)

Significant Accounting Policies

This is the Balance sheet referred to in our report of even date.

The accompanying notes are integral part of financial statements

For Nivedita & Company

Chartered Accountants
Firm Reg No. 152122W

CA. Nivedita Thatoi
(Partner)

M. No: 194052

UDIN : 24194052BKJML04992

Place : Ahmedabad

Date : 23/09/2024



**For and on behalf of the board of directors of Aneta
Pharmaceuticals Private Limited**
CIN: U24230GJ2022PTC131644

NITIN J PATEL
(Director)
DIN:05225550

SUBHASH J CHHABHAIYA
(Director)
DIN: 07090890

Place : Ahmedabad
Date : 23/09/2024



Aneta Pharmaceuticals Private Limited
CIN: U24230GJ2022PTC131644
Cash Flow Statement for the year ended on 31st March, 2023

(Rupees in Hundred, Unless otherwise Stated)

PARTICULARS	Year Ended 31-03-2024	Year Ended 31-03-2023
CASH FLOWS FROM OPERATING ACTIVITIES		
Net profit before tax & extraordinary items	(591,814)	(5,753)
Adjustments for		
Depreciation & Amortization expense	74,162	688
Gratuity Expenses	1,328	133
Provisions	64,675	17,745
Cash generated from Operations	(451,650)	12,812
Operating profit before working capital changes	(451,650)	12,812
(Increase)/Decrease in Trade Receivables	(572,882)	-
(Increase)/Decrease in Other Current Assets	(358,635)	(61,712)
(Increase)/Decrease in Loans & Advances & other current assets	(321,673)	(100,229)
Increase/(Decrease) in Trade Payables	947,231	8,973
Increase/(Decrease) in Other Liabilities & Short Term Provision	468,035	40,820
(Increase)/Decrease in Inventory	(966,393)	-
	(804,317)	(112,147)
Net income tax (paid) / refunds	-	-
Cash Generated from Operations	(1,255,967)	(99,335)
NET CASH FROM OPERATING ACTIVITIES	(1,255,967)	(99,335)
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of Property, Plant, Equipments, Net of Advances	2,599,926	790,700
NET CASH FROM INVESTING ACTIVITIES	2,599,926	790,700
CASH FLOWS FROM FINANCING ACTIVITIES		
Increase in Share Capital	-	450,000
Long Term Borrowing	2,924,748	1,577,037
Long Term Loans & advances & Other Non-Current Assets	847,793	(977,501)
NET CASH FROM FINANCING ACTIVITIES	3,772,541	1,049,537
NET CASH FLOWS	(83,351)	159,502
Cash & Cash Equivalents at the beginning of the period	159,501	-
Cash & Cash Equivalents at the end of the period	76,150	159,501

Note : The above Cash Flow Statement has been prepared under indirect method as per AS-3 "Cash Flow Statement"

As per our report of even date

For Nivedita & Company

Chartered Accountants
Firm Reg No. 152122W

CA. Nivedita Thatoi
Partner

M. No: 194052
UDIN : 241940528KJML04992
Place : Ahmedabad
Date : 23/09/2024



For and on behalf of the Board of Directors of Aneta Pharmaceuticals Private Limited

The accompanying notes are integral part of financial statements

NITIN J PATEL
(Director)
DIN:05225550

SUBHASH J CHHABHAIYA
(Director)
DIN: 07090890

Place : Ahmedabad
Date : 23/09/2024

Patel Nitin J *Subhash J Chhabhaiya*



Aneta Pharmaceuticals Private Limited
CIN: U24230GJ2022PTC131644

Notes to Financial statements for the period ended 31st March 2024

(Rupees in Hundred, Unless otherwise Stated)

Particulars	As at 31-03-2024	As at 31-03-2023
2 : Share Capital :		
Authorized Share Capital		
45,00,000 Equity shares of Rs. 10/- each	4,50,000	4,50,000
	4,50,000	4,50,000
Issued, Subscribed and Fully Paid up Share Capital		
45,00,000 Equity shares of Rs. 10/- each	4,50,000	4,50,000
	4,50,000	4,50,000

2.1 : Reconciliation of the shares outstanding at the beginning and at the end of the reporting period

Particulars	As at 31st March 2024	
	No. of Shares	Amount
Equity Share		
At the beginning of the period	45,00,000	4,50,000
Issued during the period	-	-
Outstanding at the end of the period	45,00,000	4,50,000
	As at 31st March 2023	
Equity Share	No. of Shares	Amount
At the beginning of the period	-	-
Issued during the period	45,00,000	4,50,000
Outstanding at the end of the period	45,00,000	4,50,000

2.1 : Terms/right attached to the equity shares :

The Company has only one class of equity share having a par value of Rs. 10/- per share. Each holder of equity share is entitled to one vote per share.

In the event of liquidation of the company, the holder of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.



Patel



Aneta Pharmaceuticals Private Limited
CIN: U24230GJ2022PTC131644
Notes to Financial statements for the period ended 31st March 2024

(Rupees in Hundred, Unless
otherwise Stated)

2.2 : Details of shareholders holding more than 5% shares:

Name of Shareholders	Percentage of Holding as at	Number of Shares as at
	31-03-2024	31-03-2024
Equity share of Rs. 10/- each fully paid at par		
Miteshkumar Keshavlal Patel	10%	4,50,000
Nitinbhai Patel	25%	11,25,000
Subhash Jayantibhai Chhabhaiya	25%	11,25,000
V.J.Firetech Pvt. Ltd.	20%	9,00,000
	80%	36,00,000

2.3 : Reconciliation of shares at the beginning and end of the reporting period:

Particulars	As at 31.03.2024		As at 31.03.2023	
	Number	Amount Rs.	Number	Amount Rs.
Shares Opening Balance	45,00,000	4,50,000	-	-
Adjustments	-	-	-	-
Shares issued during the period	-	-	45,00,000	4,50,000
Shares Redeemed during the year	-	-	-	-
Shares as at the end of the period	45,00,000	4,50,000	45,00,000	4,50,000

2.4 : Equity Shares held by the promoters of the Company:

Name of Promoter	As at 31.03.2024		
	No. of Shares	% of Total Shares	% Change During the Year
Nitinbhai Patel - Capital	11,25,000	25%	0%
Subhash Jayantibhai Chhabhaiya	11,25,000	25%	0%
	22,50,000	50%	



Patel

Aneta Pharmaceuticals Private Limited
CIN: U24230GJ2022PTC131644
Notes to Financial statements for the period ended 31st March 2024

(Rupees in Hundred, Unless
otherwise Stated)

Particulars	As at 31-03-2024	As at 31-03-2023
3 : Reserves and Surplus :		
Surplus in the statement of profit and loss		
Opening Balance	(5,427)	-
Additions during the year	(6,31,035)	(5,427)
Closing Balance	(6,36,462)	(5,427)

Particulars	As at 31-03-2024	As at 31-03-2023
4 : Long Term Borrowings:		
Term Loan (Secured)		
- From Bank	20,41,366	10,66,971
Rupee Term loan from HDFC Bank O/s. Balance Rs. 21,98,98,414/- (Secured against Plant & Machinery, Stock, Book Debts & Fixed Deposit) - The Term Loan is repayable in 96 monthly Installments starting from 15/08/2023 and ending on 15/08/2031.	-	
Vehicle- Bus loan from HDFC Bank O/s. Balance Rs.54,72,403/- (Secured against Hypothication of Bus) - The Vehicle Loan is repayable in 60 monthly Installments starting from 5/02/2024 and ending on 5/01/2029.	-	
Deposits (Unsecured)		
- From Member (Share Holder)	1,65,560	1,15,560
- Inter Corporate Deposit	6,33,320	1,80,320
Loans and Advances from related parties		
(i) Unsecured loans from directors (Not repayble within 12 months from the date of Balance sheet)	16,61,539	2,14,186
Closing Balance	45,01,785	15,77,037

Particulars	As at 31-03-2024	As at 31-03-2023
5 : Long Term Provisions :		
Provision for Employee Benefits		
Gratuity (Refer Note 29)	1,453	132
Others	-	-
	1,453	132

Particulars	As at 31-03-2024	As at 31-03-2023
6 : Deferred Tax / Liability :		
Deferred Tax Assets:		
Arising on account of timing difference in :		
Property Plant & Equipments	(39,814)	(103)
Employee benefits	919	429
Deferred Tax Assets	(38,895)	326



Dated 10/04/24

Aneta Pharmaceuticals Private Limited
CIN: U24230GJ2022PTC131644
Notes to Financial statements for the period ended 31st March 2024

(Rupees in Hundred, Unless
otherwise Stated)

Particulars	As at 31-03-2024	As at 31-03-2023
8 : Other Current Liabilities :		
Statutory Dues Payable	47,162	3,116
Creditors for Capital Expenditure	31,688	7,449
Advance received From customer	26,620	-
	1,05,470	10,565

Particulars	As at 31-03-2024	As at 31-03-2023
9 : Short Term Borrowing :		
Term Loan (Secured)	1,95,433	29,306
- From Bank		
Rupee Term loan from HDFC Bank O/s. Balance Rs. 21,98,98,414/- (Secured against Plant & Machinery, Stock, Book Debts & Fixed Deposit) - The Term Loan is repayable in 96 monthly Installments starting from 15/08/2023 and ending on 15/08/2031.		
Loan Repayble on Demand (Unsecured)		
- From Bank	2,07,952	949
	4,03,385	30,255

Particulars	As at 31-03-2024	As at 31-03-2023
10 : Short Term Provisions :		
Provision for Income Tax		-
Provision for employee benefits (Gratuity) (Refer Note 29)	7	0
	7	0



Patel

Aneta Pharmaceuticals Private Limited

CIN: U24230GJ2022PTC131644

Notes to Financial statements for the period ended 31st March 2024

(Rupees in Hundred, Unless otherwise Stated)

7 : Trade Payable :

Particulars	As at	
	31-03-2024	31-03-2023
- Total outstanding dues of micro enterprises and small	2,53,749	
- Total outstanding dues of creditors other than micro	7,84,874	26,718
(Refer Note 27 for disclosure of MSME)	10,38,624	26,718

7.1 : Aging of Trade Payable

Particulars	Outstanding for following periods from due date of payment				Total
	Not due for payment	As at 31st March 2024			
		Less than 1 year	1 to 2 years	2 to 3 years	
MSME	-	-	-	-	2,53,749
Others	1,24,564	6,60,310	-	-	7,84,874
Disputed dues MSME	-	-	-	-	-
Disputed dues Others	-	-	-	-	-
	1,24,564	9,14,059	-	-	10,38,624

7.1 : Aging of Trade Payable

Particulars	Outstanding for following periods from due date of payment				Total
	Not due for payment	As at 31st March 2023			
		Less than 1 year	1 to 2 years	2 to 3 years	
MSME	-	-	-	-	2,230
Others	20,091	4,397	-	-	24,488
Disputed dues MSME	-	-	-	-	-
Disputed dues Others	-	-	-	-	-
	20,091	6,628	-	-	26,718



Patel

Aneta Pharmaceuticals Private Limited
 CTIN: U24230GJ2022PTC131644

Notes to Financial statements for the period ended 31st March 2024

(Rupees in Hundred, Unless otherwise Stated)

Sr. No.	Particulars	Gross Block		As on 31/03/2024	Up to 01/04/2023	Depreciation/Impairment		Net Carrying amount		
		As at 1/04/2023	Addition			Disposal/Adjustment	Addition	Deletions/Adjustment	Upto 31/03/2024	As on 31/03/2024
1	Land	-	-	-	-	-	-	-	-	-
2	Building	-	2,78,572	2,78,572	-	2,945	-	2,945	2,75,627	-
3	Computer Systems	1,888	9,370	11,259	425	1,731	-	2,156	9,103	1,463
4	Furniture & Fixtures	-	25,051	25,051	-	666	-	666	24,385	-
5	Office Equipments	1,062	38,152	39,215	25	3,004	-	3,029	36,186	1,037
6	Plant and Machinery	-	25,45,413	25,45,413	-	51,758	-	51,758	24,93,655	-
7	Electrical Installations	-	1,85,082	1,85,082	-	3,999	-	3,999	1,81,084	-
8	Plant and Equipment (Laboratory Equipments)	-	2,50,369	2,50,369	-	7,770	-	7,770	2,42,599	-
9	Motor Vehicles	-	50,345	50,345	-	1,440	-	1,440	48,905	-
	Total	2,951	33,82,355	33,85,306	450	73,313	-	73,763	33,11,544	2,500
	Previous Year Figures	-	2,951	2,951	-	450	-	450	2,500	-



Pate 10/1/24



(Rupees in Hundred, Unless otherwise Stated)

Sr. No.	Particulars	Gross Block			Depreciation/Impairment			Net Carrying amount		
		As at 1/04/2023	Addition	Disposal	As on 31/03/2024	Upto 01/04/2023	Addition	Deletions/Adjustment	Upto 31/03/2024	Upto 31/03/2023
1	Intangible Assets	1,120	4,200	-	5,320	238	849	-	4,233	882
	Computer Software	1,120	4,200	-	5,320	238	849	-	4,233	882
	Total	1,120	4,200	-	5,320	238	849	-	4,233	882
	Previous Year Figures	-	1,120	-	1,120	-	238	-	882	-

13 : Capital Work in Progress :

A CWIP aging schedule as at 31-03-2024

CWIP Projects in progress Total	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
-	-	-	-	-	-
-	-	-	-	-	-

CWIP aging schedule as at 31-03-2023

CWIP Projects in progress	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
7,86,629	-	-	-	-	7,86,629



Ratna K. Bhatnagar

Aneta Pharmaceuticals Private Limited

CIN: U24230GJ2022PTC131644

Notes to Financial statements for the period ended 31st March 2024

(Rupees in Hundred, Unless otherwise Stated)

Particulars	As at 31-03-2024	As at 31-03-2023
16 : Trade Receivables :		
Unsecured, considered good		
Outstanding for a period exceeding six months from the date they	-	-
Other trade receivables	5,72,882	-
(See note 20.2 for trade receivables from related parties)	5,72,882	-

16.1 : Aging of Trade Receivables

Particulars	Not due for payment	Outstanding from due date of payment					Total
		Unbilled	Less than 6 Month	6 Month to 1 year	1 to 2 Years	2 to 3 Years	
		As at 31st March 2024					
Undisputed - considered good	-	-	5,64,075	8,807	-	-	5,72,882
Undisputed - considered doubtful	-	-	-	-	-	-	-
Disputed - considered good	-	-	-	-	-	-	-
Disputed - considered doubtful	-	-	-	-	-	-	-
Total	-	-	5,64,075	8,807	-	-	5,72,882

Particulars	Not due for payment	Outstanding from due date of payment					Total
		Unbilled	Less than 6 Month	6 Month to 1 year	1 to 2 Years	2 to 3 Years	
		As at 31st March 2023					
Undisputed - considered good	-	-	-	-	-	-	-
Undisputed - considered doubtful	-	-	-	-	-	-	-
Disputed - considered good	-	-	-	-	-	-	-
Disputed - considered doubtful	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-



Pate 1

Aneta Pharmaceuticals Private Limited

CIN: U24230GJ2022PTC131644

Notes to Financial statements for the period ended 31st March 2024

(Rupees in Hundred, Unless otherwise Stated)

Particulars	As at 31-03-2024	As at 31-03-2023
14 : Long Term Loans & Advances:		
Others		
(i) Advance for Capital Goods	560	8,76,560
Total	560	8,76,560

Particulars	As at 31-03-2024	As at 31-03-2023
15 : Other Non Current Assets:		
Security Deposits	41,585	37,535
Bank Deposits	87,562	63,406
In Deposits Accounts (Fixed deposits of Rs. 84,29,221/- pledged against bank guarantees) with Maturity after 1 Year from balance sheet date.	-	-
Total	1,29,147	1,00,941

Particulars	As at 31-03-2024	As at 31-03-2023
17 : Cash and Bank Balances :		
(a) Balance With Bank in current account	-	16,191
(b) Cash On Hand	780	1
(c) Bank Deposit	75,370	1,43,309
In Deposits Accounts (Fixed deposits of Rs. 75,37,049/- pledged against bank guarantees) with Maturity less than 1 Year from balance sheet date.	-	-
Total	76,150	1,59,501

Particulars	As at 31-03-2024	As at 31-03-2023
18: Inventories		
(At lower of Cost and Net Realisable Value)		
(a) Raw Materials	1,71,940	-
(b) Work-In- Progress	81,083	-
(c) Finished goods	90,966	-
(d) Stock in Trade	6,22,405	-
Total	9,66,393	-

Particulars	As at 31-03-2024	As at 31-03-2023
19 : Short Term Loans and Advances :		
Advance given to Suppliers	4,21,902	1,00,229
Total	4,21,902	1,00,229

Particulars	As at 31-03-2024	As at 31-03-2023
20 : Other Current Assets :		
Prepaid Expenses	-	-
Balance with Government Authorities	4,20,347	60,396
Interest accrued	-	1,315
Total	4,20,347	61,712



Patel

Aneta Pharmaceuticals Private Limited
CIN: U24230GJ2022PTC131644
Notes to Financial statements for the period ended 31st March 2024

(Rupees in Hundred, Unless
otherwise Stated)

Particulars	Year Ended 31-03-2024	Year Ended 31-03-2023
21 : Revenue from Operations :		
sale of products	8,96,187	3,27,527
	<u>8,96,187</u>	<u>3,27,527</u>
22 : Other Income :		
Interest Income	13,259	4,054
	<u>13,259</u>	<u>4,054</u>
23: Cost of Material Consumed		
Raw Material Including Packing Material at the Beginning of the year	-	-
Add: Purchase	3,58,497	-
Less: Raw materials including packing materials at the end of the year	1,71,940	-
	<u>1,86,557</u>	<u>-</u>
24: Purchase of Stock In Trade		
Purchase of Stock in trade	13,55,257	3,24,885
	<u>13,55,257</u>	<u>3,24,885</u>
25 : Changes in inventories of finished goods, work-in-progress and stock in-trade		
Opening Stock	-	-
Finished Goods	-	-
Stock in Trade	-	-
Work-in Progress	-	-
Less Closing Stock		
Finished Goods	90,966	-
Stock in Trade	6,22,405	-
Work-in Progress	81,083	-
	<u>7,94,453</u>	<u>-</u>
Total changes in inventories of finished goods, work-in-progress and stock-in-trade	<u>(7,94,453)</u>	<u>-</u>
26 : Employee Benefits Costs :		
Salaries, Allowances, Contributions	3,30,404	4,178
27: Finance Cost		
(a) Interest expense on borrowings - Term Loan	72,698	
Cash Credit/Over Draft	7,320	
INTEREST EXPENSE- Inter corporate Deposit	137	
Total interest expense for financial liabilities	<u>80,155</u>	<u>-</u>
Other Finance Cost	176	
	<u>80,331</u>	<u>-</u>



Patel

Aneta Pharmaceuticals Private Limited
CIN: U24230GJ2022PTC131644
Notes to Financial statements for the period ended 31st March 2024

(Rupees in Hundred, Unless
otherwise Stated)

Particulars	Year Ended 31-03-2024	Year Ended 31-03-2023
28 : Other Expenses :		
Computer And Internet Expenses	1,135	418
Freight And Transportation	401	16
Plant Expenses	43,800	-
Insurance	1,665	-
Intrest Expense	-	23
Legal And Professional Fees	3,510	50
Miscellaneous	3,212	282
Office Expenses	18,461	101
Rates And Taxes	29,292	5,785
Repars And Maintenance	18,437	249
Telecommunication Expenses	334	146
Travelling Expenses	6,810	213
Utility Charges	39,951	300
Selling And Distribution Exp	57,583	-
Laboratory Expenses	13,484	-
Donation	456	-
Staff Wifare Expenses	150	-
Transport Cost	1,579	-
Purchase Of Stock In Trade	156	-
Labour Expenses	600	-
Meal & Entertainment Expenses	3,344	-
Packing Expenses Trading	2,328	-
Product Rehistration Charges	297	-
Rent	18,348	-
Security Expenses	3,670	-
	2,69,004	7,583
27.1 : Payment To Auditors :		
Audit Fees	2,000	2,000
	2,000	2,000



Patel

Aneta Pharmaceuticals Private Limited
CIN: U24230GJ2022PTC131644
Notes to Financial statements for the period ended 31st March 2024

(Rupees in Hundred, Unless otherwise Stated)

29 : Related Party Disclosure:

Relationship Related Parties:

(a) Key Management Personnel

Name of the Management Personnel	Type
Mr. Nitin j Patel	Director
Mr. Rameshbhai Khimjibhai Patel	Director
Mr. Subhash J chhabhaiya	Director

(b) Relatives Of Director

Name of the Relative	Type Relation
Mr. Bhavik Jayantibhai Chhabhaiya	Brother of Director
Mr. Harshadkumar Jashvantil Patel	Brother of Director

(c) Entities Controlled by Directors/Relative of Directors

Name of the Directors	Name of the Entities
Mr. Nitin j Patel	Accent Microcell Ltd.
Mr. Subhash J chhabhaiya	Indocon Infrastructure Pvt. Ltd.
Mr. Nitin j Patel	Globe Star Valves Private Limited
Mr. Nitin j Patel	Indo Smc Pvt. Ltd.

(d) Investors in respect of which reporting enterprise is an associate or Joint venture:


Name of the organisation	Nature of relationship
V.J Fire tech Pvt. Ltd.	Associate

29.1 Transactions with related parties :

Particulars	Key Management Personnel	Relatives of Directors	Enterprise over which significant influence exercised by directors	Investors in respect of which reporting enterprise is an associate/ JV
Sale of Goods			0 (309073)	
Loan taken	1552352 (5,32,561)			
Loan Outstanding as on 31/03/24	1661539 (198223)			
Inter corporate deposit			50000 (0)	
Interest on Inter corporate deposit			137 (0)	
Inter corporate deposit				353000 (175000)
Purchase of Raw Material			10857 (0)	
Purchase of Services		206 (0)		
Purchase of capital goods		41382 (218870)		
Purchase of capital goods				39,165

30: Earning Per Share :

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Profit attributable to Share Holders	(6,31,035)	(5,427)
Basic/Weighted Average No. of Equity Shares O/s during Year ('00)	4,500	4,500
Nominal Value of Equity Shares (Rs.)	10	10
Basic/Diluted Earning per Share (Rs.)	(140)	(1)



Patel

Aneta Pharmaceuticals Private Limited
CIN: U24230GJ2022PTC131644
Notes to Financial statements for the period ended 31st March 2024

(Rupees in Hundred, Unless otherwise Stated)

31 : Details of Foreign Exchange Transactions :

31.1 Expenditure in foreign currency :

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Import of Capital Goods	-	-
Import of Material and Services	19,998	-

31.2 Earning in foreign currency :

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
	-	-

31.3 Net dividend remitted in foreign exchange :

The Company has not issued any Dividend and also no remittance for the same is made.

32 : Disclosure regarding company being a SMC :

The Company is a Small and Medium Sized Company (SMC) as defined in the General Instructions in respect of Accounting Standards notified under the Companies Act, 2013. Accordingly, the Company has complied with the Accounting Standards as applicable to a Small and Medium Sized Company.

33 : Disclosure of information pertaining to Micro, Small and Medium Enterprises :

The Company has received intimation from majority of "Suppliers" regarding their status under the Micro, Small and Medium Enterprise Development Act, 2006. The "Supplier" who not response is consider as non MSME.

Sl. No	Particulars	As on	As on
		March 31,2024	March 31,2023
1	Principal amount due to suppliers registered under the MSMED Act and remaining unpaid as at year end	2,53,749	2,230
2	Interest due to suppliers registered under the MSMED Act and remaining unpaid as at year end	4,223	-
3	Principal amounts paid to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
4	Interest paid, other than under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
5	Interest paid, under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
6	Interest due and payable towards suppliers registered under MSMED Act, for payments already made	-	-
7	Further interest remaining due and payable for earlier years	-	-

34 : Subsequent Event :

There is no any subsequent event has taken place which has material impact on the financials as on 31 March, 2023.

35 : Employee benefits :

- a) The company Provident Fund Act is not applicable to company as on Period under consideration or at year end as No. of employee employe by the copmany is less than 20.
- b) Under the gratuity plan, every employee who has completed at least five years of service gets a gratuity on departure at the rate of 15 days of last drawn salary for each completed year of service. The plan is not funded by the company.

The following tables summarize the components of net benefit expense recognized in the statement of profit and loss and amounts recognized in the balance sheet for the respective plans:

Statement of profit and loss

Net employee benefit expense recognized in the employee cost:

Particulars	Year ended 31-03-2024 Rs.	Year ended 31-03-2023 Rs.
Current service cost	2,569	133
Past service cost - Plan Amendment	-	-
Interest cost on benefit obligation	10	-
Expected return on plan assets	-	-
Net actuarial (gain)/loss recognized in the year	(1,251)	-
Net benefit expense	1,328	133



Patel

Aneta Pharmaceuticals Private Limited

CIN: U24230GJ2022PTC131644

Notes to Financial statements for the period ended 31st March 2024

(Rupees in Hundred, Unless otherwise Stated)

Particulars	Year ended 31-03-2024 Rs.	Year ended 31-03-2023 Rs.
Balance sheet		
Benefit asset/liability		
Present value of defined benefit obligation	1,460	133
Fair value of plan assets	-	-
Present value of defined benefit obligation	1,460	133

Changes in the present value of the defined benefit obligation are as follows:

Particulars	Year ended 31-03-2024 Rs.	Year ended 31-03-2023 Rs.
Opening defined benefit obligation	133	-
Current service cost	2,569	133
Past service cost - Plan Amendment	-	-
Interest cost	10	-
Benefits paid	-	-
Actuarial (gains)/losses on obligation	(1,251)	-
Closing defined benefit obligation	1,460	133

The principal assumptions used in determining gratuity for the company's plans are shown below:

Particulars	Year ended 31-03-2024	Year ended 31-03-2023
Discount rate	7.16% p.a.	7.49% p.a.
Expected rate of return on assets	N.A.	N.A.
Salary Escalation Rate	7%	7%
Withdrawal rate	24%	3%
Mortality	Indian Assured Lives Mortality 2012-14 (Urban)	Indian Assured Lives Mortality 2012- 14 (Urban)

36 : Fund

No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries") with the understanding, whether recorded in writing or otherwise, that the Intermediary shall lend or invest in party identified by or on behalf of the Company (Ultimate Beneficiaries). The Company has not received any fund from any party(s) (Funding Party) with the understanding that the Company shall whether, directly or indirectly lend or invest in other persons or entities identified by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

37 : Security Code

The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits has received Presidential assent on

38 : Segment reporting

The Company is operating in the single segment i.e Trading & manufacture on "Pharmaceutical Products", therefore, segment reporting is not applicable during the

39 : Amendments to Schedule III

ICAI is currently upgrading the Accounting Standards under Companies (Accounting Standards) Rules, 2021 to align them with Indian Accounting Standards. The revised Accounting Standards, totaling 32 standards, are being developed and will replace the existing standards. Currently, 24 revised standards have been issued as Exposure Drafts. The impact of these standards will be evaluated by the management once they are officially released and implemented together at a future date.

40 : Capital Commitment

Contracts outstanding as on 31 March 2023 on account of capital commitments aggregate to INR 0 (PY- 5,20,601.74/-)

41 Other disclosures with regards to Division I of Schedule III to the Companies Act, 2013 are either NIL or not applicable to the Company

Previous year figures have been regrouped/reclassified wherever required.



Aneta Pharmaceuticals Private Limited
CIN: U24230GJ2022PTC131644
Notes to Financial statements for the year ended 31st March 2023

43 : ANALYTICAL RATIOS:

Sr. No	Ratio	Numerator	Denominator	FY 23-24	FY 22-23	% Change	Reason for Change
1	Current Ratio	Current Assets	Current Liabilities	1.59	4.76	3.17	Company has started manufacturing Operation in November 23 Which Impact Ratio
2	Debt-Equity Ratio	Total Debt	Shareholder's Equity	(26.31)	3.55	29.85	Company has started manufacturing Operation in November 23 Which Impact Ratio
3	Debt Service Coverage Ratio	Earnings available for debt service	Finance cost + Repayment of debt	(7.40)	NA	(7.40)	Company has started manufacturing Operation for which company borrow fund from bank
4	Return on Equity Ratio	Net Profits after taxes	Average Shareholder's Equity	-122%	-1%	1.22	Company has started manufacturing Operation in November 23 due to which company incurred loss
5	Inventory turnover ratio	Net Sales	Average Inventory	1.85	NA	1.85	Company has started manufacturing Operation in November 23 Which Impact Ratio
6	Trade Receivables turnover ratio	Net Sales	Average Trade Receivables	3.13	NA	3	Company has started their Trading activity and manufacturing Operation during the year which Impact Ratio
7	Trade payables turnover ratio	Net Purchases and Other Expenses	Average Trade Payables	2.97	6	3.11	Company has started their Trading activity and manufacturing Operation during the year which Impact Ratio
8	Net capital turnover ratio	Net Sales	Average Working Capital	1.97	258%	0.61	Company has started their Trading activity and manufacturing Operation during the year which Impact Ratio
9	Net profit ratio	Net Profits after taxes	Net Sales	-70%	-2%	0.69	Company has started manufacturing Operation in November 23 due to which company incurred loss
10	Return on Capital employed	Earnings before interest and taxes	Average Capital Employed	-27%	-1%	0.27	Company has started manufacturing Operation in November 23 due to which company incurred loss
11	Return on investment	Income from investments	Time weighted average of investments	NA	NA		

Net: As Borrowing Cost is Capitalized as per Accounting Standard on Eligible Assets and as a First Year company has incurred lost Debt Service Coverage ratio is Not Applicable

For Nivedita & Company

Chartered Accountants
Firm Reg No 152122W

CA. Nivedita Thatoi
(Partner)
M. No: 194652
UDIN :

Place Ahmedabad
Date : 23/09/2024



For and on behalf of the board of directors of Aneta
Pharmaceuticals Private Limited

CIN: U24230GJ2022PTC131644

Patel
NITIN J PATEL
(Director)

SUBHASH J CHHARRAIYA
(Director)
DIN:05222550
DIN: 07090890

Place : Ahmedabad
Date : 23/09/2024

